|
US10227408B2
(en)
|
2015-02-19 |
2019-03-12 |
Compugen Ltd. |
Anti-PVRIG antibodies and methods of use
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
CN117964732A
(zh)
|
2015-08-07 |
2024-05-03 |
Alx肿瘤生物技术公司 |
具有SIRP-α结构域或其变体的构建体
|
|
WO2017184553A1
(en)
*
|
2016-04-18 |
2017-10-26 |
Baylor College Of Medicine |
Cancer gene therapy targeting cd47
|
|
US12344669B2
(en)
|
2016-06-17 |
2025-07-01 |
Changchun Genescience Pharmaceutical Co., Ltd. |
Anti-CD47 monoclonal antibody and use thereof
|
|
CN106084052B
(zh)
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
CA3029977A1
(en)
|
2016-07-06 |
2018-01-11 |
Celgene Corporation |
Antibodies with low immunogenicity and uses thereof
|
|
WO2018012952A1
(ko)
*
|
2016-07-15 |
2018-01-18 |
한국과학기술연구원 |
신규 나노케이지 및 그의 용도
|
|
CN112274637A
(zh)
|
2016-08-17 |
2021-01-29 |
康姆普根有限公司 |
抗tigit抗体、抗pvrig抗体及其组合
|
|
CA2999058C
(en)
*
|
2016-10-20 |
2024-03-12 |
I-Mab |
Novel cd47 monoclonal antibodies and uses thereof
|
|
CA3042583A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Improvements in cd47 blockade therapy by hdac inhibitors
|
|
JP7262440B2
(ja)
*
|
2017-08-02 |
2023-04-21 |
フェインズ セラピューティクス，インコーポレーテッド |
抗ｃｄ４７抗体及びその使用
|
|
ES2911243T3
(es)
*
|
2017-08-10 |
2022-05-18 |
Grifols Diagnostic Solutions Inc |
Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano
|
|
JP7256580B2
(ja)
|
2017-08-18 |
2023-04-12 |
ウルトラヒューマン フォー リミティド |
結合剤
|
|
EP3710048A4
(en)
*
|
2017-11-17 |
2021-08-18 |
University of Massachusetts |
HUMANIZED MONOCLONAL 2C7 ANTIBODY DIRECTED AGAINST LIPOOLIGOSACCHARIDE (LOS) EPITOPE ANEISSERIA GONORRHOEAE
|
|
KR20200091901A
(ko)
|
2017-12-01 |
2020-07-31 |
시애틀 지네틱스, 인크. |
암을 치료하기 위한 cd47 항체 및 이의 용도
|
|
CN110144009B
(zh)
*
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
|
GB201804860D0
(en)
*
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
CN110577597B
(zh)
|
2018-06-11 |
2021-10-22 |
康诺亚生物医药科技（成都）有限公司 |
一种阻断CD47和SIRPα相互作用的抗体
|
|
US11634490B2
(en)
|
2018-06-15 |
2023-04-25 |
Accurus Biosciences, Inc. |
Blocking antibodies against CD47 and methods of use thereof
|
|
CN109053882B
(zh)
*
|
2018-08-28 |
2019-08-23 |
东莞市朋志生物科技有限公司 |
一种ns1蛋白的结合蛋白以及应用
|
|
CN110872350B
(zh)
*
|
2018-08-31 |
2023-04-07 |
南京圣和药业股份有限公司 |
抗cd47抗体及其应用
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
MX2021010265A
(es)
|
2019-02-26 |
2021-09-23 |
Janssen Biotech Inc |
Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
|
|
WO2020215012A1
(en)
*
|
2019-04-18 |
2020-10-22 |
Qlsf Biotherapeutics Inc. |
Antibodies that target human cd47
|
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
JOP20210304A1
(ar)
|
2019-05-14 |
2023-01-30 |
Janssen Biotech Inc |
علاجات مركبة باستخدام الأجسام المضادة ثنائية النوعية المضادة لمستقبل عامل نمو البشرة (EGFR)/ مستقبل عامل نمو خلايا الكبد (c-Met) ومثبطات كيناز التيروسين الخاصة بمستقبل عامل نمو البشرة (EGFR) من الجيل الثالث
|
|
AU2020282791A1
(en)
|
2019-05-31 |
2021-12-09 |
ALX Oncology Inc. |
Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
|
|
MA56119A
(fr)
|
2019-06-07 |
2022-04-13 |
Alx Oncology Inc |
Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques
|
|
CA3145791A1
(en)
|
2019-07-16 |
2021-01-21 |
Gilead Sciences, Inc. |
Hiv vaccines and methods of making and using
|
|
CN114981409A
(zh)
|
2019-09-03 |
2022-08-30 |
美洛德生物医药公司 |
用于基因组整合的方法和组合物
|
|
MX2022004370A
(es)
|
2019-10-18 |
2022-05-06 |
Forty Seven Inc |
Terapias de combinacion para tratar sindromes mielodisplasicos y leucemia mieloide aguda.
|
|
AU2020372522B2
(en)
|
2019-10-25 |
2024-08-15 |
WuXi Biologics Ireland Limited |
Novel anti-CD47 antibodies and uses thereof
|
|
WO2021087064A1
(en)
|
2019-10-31 |
2021-05-06 |
Forty Seven, Inc. |
Anti-cd47 and anti-cd20 based treatment of blood cancer
|
|
BR112022008817A2
(pt)
|
2019-11-27 |
2022-07-26 |
Alx Oncology Inc |
Terapias combinadas para tratamento de câncer
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
JP7711068B2
(ja)
|
2019-12-24 |
2025-07-22 |
カルナバイオサイエンス株式会社 |
ジアシルグリセロールキナーゼ調節化合物
|
|
JOP20220184A1
(ar)
|
2020-02-12 |
2023-01-30 |
Janssen Biotech Inc |
علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14
|
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
|
WO2021191870A1
(en)
|
2020-03-27 |
2021-09-30 |
Dcprime B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
JP2023531537A
(ja)
|
2020-06-30 |
2023-07-24 |
メンドゥス・ベスローテン・フェンノートシャップ |
卵巣癌ワクチンでの白血病由来細胞の使用
|
|
JP7789304B2
(ja)
*
|
2020-07-31 |
2025-12-22 |
バイオ－テラ ソリュ－ションズ，エルティーディー． |
Ｃｄ４７抗体及びその応用
|
|
WO2022098642A1
(en)
|
2020-11-03 |
2022-05-12 |
Rdiscovery, LLC |
Therapies for treatment of cancer and phagocytosis-deficiency related diseases
|
|
EP4240367A4
(en)
|
2020-11-04 |
2024-10-16 |
Myeloid Therapeutics, Inc. |
MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4256336A1
(en)
|
2020-12-06 |
2023-10-11 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
JP2024503822A
(ja)
*
|
2021-01-05 |
2024-01-29 |
ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン |
Ｇｐｃ３及びｃｄ４７を標的とする二重特異性抗体
|
|
JP7699210B2
(ja)
*
|
2021-01-08 |
2025-06-26 |
北京韓美薬品有限公司 |
Ｃｄ４７と特異的に結合する抗体及びその抗原結合フラグメント
|
|
CA3212351A1
(en)
|
2021-03-12 |
2022-09-15 |
Mendus B.V. |
Methods of vaccination and use of cd47 blockade
|
|
CA3212398A1
(en)
|
2021-03-17 |
2022-09-22 |
Daniel Getts |
Engineered chimeric fusion protein compositions and methods of use thereof
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
CA3218780A1
(en)
|
2021-05-11 |
2022-11-17 |
Daniel Getts |
Methods and compositions for genomic integration
|
|
JP2024520902A
(ja)
|
2021-05-13 |
2024-05-27 |
エーエルエックス オンコロジー インコーポレイテッド |
がんを治療するための併用療法
|
|
KR20240025616A
(ko)
|
2021-06-23 |
2024-02-27 |
길리애드 사이언시즈, 인코포레이티드 |
다이아실글리세롤 키나제 조절 화합물
|
|
AU2022298639C1
(en)
|
2021-06-23 |
2025-07-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CN117881698A
(zh)
*
|
2021-06-30 |
2024-04-12 |
创新生物有限公司 |
对cd47具有特异性的人源化抗体及包含其的用于预防或治疗cd47相关疾病的药物组合物
|
|
JP2024539252A
(ja)
|
2021-10-28 |
2024-10-28 |
ギリアード サイエンシーズ， インコーポレイテッド |
ピリジジン－３（２ｈ）－オン誘導体
|
|
CA3235986A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Science, Inc. |
Cd73 compounds
|
|
EP4667056A1
(en)
|
2021-12-22 |
2025-12-24 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114371282B
(zh)
*
|
2021-12-30 |
2025-07-11 |
上海药明生物技术有限公司 |
一种评估抗原沉默效应对抗体药效影响的方法及其应用
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
LT4245756T
(lt)
|
2022-03-17 |
2024-11-25 |
Gilead Sciences, Inc. |
Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
IL317958A
(en)
|
2022-07-01 |
2025-02-01 |
Gilead Sciences Inc |
CD73 compounds
|
|
JP2025523043A
(ja)
|
2022-07-12 |
2025-07-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖ免疫原性ポリペプチド及びワクチン、並びにその使用
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4630034A2
(en)
|
2022-12-09 |
2025-10-15 |
Pfizer Inc. |
Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy
|
|
KR20250116736A
(ko)
|
2022-12-09 |
2025-08-01 |
화이자 인코포레이티드 |
Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법
|
|
CN118221812A
(zh)
*
|
2022-12-14 |
2024-06-21 |
上海迈石生物技术有限公司 |
一种靶向cd47的单克隆抗体及其应用
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2023415274A1
(en)
*
|
2022-12-29 |
2025-06-26 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-cd47 antibodies and methods of use
|
|
KR20250158056A
(ko)
|
2023-03-13 |
2025-11-05 |
얀센 바이오테크 인코포레이티드 |
이중특이성 항-egfr/c-met 항체 및 항-pd-1 항체를 사용한 병용 요법
|
|
EP4695260A1
(en)
|
2023-04-11 |
2026-02-18 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20250175331A
(ko)
|
2023-04-21 |
2025-12-16 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024300557A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|